Li Yanhua, Wei Suju
Department of Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Zhongguo Fei Ai Za Zhi. 2013 Dec;16(12):676-80. doi: 10.3779/j.issn.1009-3419.2013.12.11.
Recently, researchers have been increasingly finding coagulation disorders are commonly the first sign of malignancy. It has now been established that cancer development leads to an increased risk of thrombosis, and conversely, excessive activation of blood coagulation profoundly influences cancer progression. In patients with lung cancer, a sustained stimulation of blood coagulation takes place. Cancer cells trigger coagulation through expression of tissue factor, and affect coagulation through expression of thrombin, release of microparticles that augment coagulation and so on. Coagulation also facilitates tumour progression through release of platelet granule contents, inhibition of natural killer cells and recruitment of macrophages. Non-small cell lung cancer (NSCLC) accounts for about 80%-85% of all lung malignancies. In the present review, we summarized the newly updated data about the physiopathological mechanisms of various components of the clotting system in different stages of carcinogenesis in NSCLC.
最近，研究人员越来越多地发现凝血障碍通常是恶性肿瘤的首个迹象。现已证实，癌症发展会导致血栓形成风险增加，反之，血液凝固的过度激活会深刻影响癌症进展。在肺癌患者中，会发生持续的凝血刺激。癌细胞通过组织因子的表达触发凝血，并通过凝血酶的表达、释放增强凝血的微粒等影响凝血。凝血还通过释放血小板颗粒内容物、抑制自然杀伤细胞和募集巨噬细胞促进肿瘤进展。非小细胞肺癌（NSCLC）约占所有肺恶性肿瘤的80%-85%。在本综述中，我们总结了关于NSCLC致癌不同阶段凝血系统各成分生理病理机制的最新数据。
